Agios Pharmaceuticals, Inc. reports developments as a commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its recurring updates center on mitapivat, an oral pyruvate kinase activator marketed as PYRUKYND® and AQVESME™, including product revenue, U.S. and ex-U.S. commercialization, thalassemia approvals, and activity in pyruvate kinase deficiency, sickle cell disease, and other hemolytic anemias.
Company news also covers FDA interactions, supplemental application activity, conference presentations, and pipeline progress for tebapivat, a next-generation PK activator, and other rare disease programs. International commercialization themes include regulatory approvals and distribution activity in Gulf Cooperation Council markets through NewBridge Pharmaceuticals.
Agios Pharmaceuticals has announced that clinical data for mitapivat and ivosidenib will be presented at the European Hematology Association (EHA) Annual Congress from June 11-14, 2020. Key presentations include interim results from a phase 2 study of mitapivat for non-transfusion-dependent thalassemia and results showing ivosidenib improves survival in mutant IDH1 acute myeloid leukemia (AML). A virtual investor event will also be held on June 12, 2020, to discuss these findings.
Agios Pharmaceuticals (NASDAQ:AGIO) announced its participation in the RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020, at 3:40 p.m. ET. A live webcast of the event will be available in the Investors section of Agios' website, with a replay accessible for two weeks post-event. The firm specializes in cellular metabolism to tackle cancer and rare genetic diseases, boasting a robust pipeline that includes two approved precision medicines and various investigational therapies. For further details, visit www.agios.com.
Summary not available.